Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma - PubMed
12 hours ago
- #immunotherapy
- #body composition
- #renal cell carcinoma
- Nivolumab plus ipilimumab is a first-line standard for metastatic clear cell renal cell carcinoma (ccRCC), but outcomes vary.
- Higher body mass index (BMI) has been linked to better outcomes in some cancers, but BMI is an imprecise measure of body composition.
- The study evaluated the association between body composition (measured via CT scans) and outcomes in metastatic ccRCC patients treated with nivolumab plus ipilimumab.
- Greater subcutaneous adiposity (SATi) and skeletal muscle mass (SMMi) were independently associated with shorter progression-free survival (PFS).
- BMI, visceral adiposity, and skeletal muscle density showed inconclusive associations with PFS and overall survival (OS).
- Single-cell RNA sequencing suggested that low SMMi correlated with higher T-cell fractions and lower myeloid cell proportions.
- The findings indicate that host body composition influences the efficacy of immune checkpoint inhibitor therapy in metastatic ccRCC.